The impact of early phase price agreements on prices of orphan drugs
Abstract Background Innovative orphan drugs often have an incremental cost-effectiveness ratio (ICER) which is higher than the maximum threshold for reimbursement. Payers have limited budgets and often cannot pay the full price of a new product, but pharmaceutical and biotechnology companies require...
Main Authors: | Mark Nuijten, Philippe Van Wilder |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12913-021-06208-7 |
Similar Items
-
Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01) -
Pricing Zolgensma – the world’s most expensive drug
by: Mark Nuijten
Published: (2022-12-01) -
Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023-01-01) -
The impact of patent expiry on drug prices: insights from the Dutch market
by: Simon van der Schans, et al.
Published: (2021-01-01) -
Establishing a reasonable price for an orphan drug
by: Mikel Berdud, et al.
Published: (2020-09-01)